Key result
Guideline-directed medical therapy, devices, and revascularization target CAD to reduce heart failure morbidity and mortality.
This review highlights that managing coronary artery disease with pharmacotherapy, electrophysiological devices, and individualized revascularization strategies is essential to reducing morbidity and mortality in heart failure patients.
Answers are grounded in this paper and cite their sources.
Supports CAD-directed therapies in HF; leaves open the role of emerging agents pending randomized trials.
Coronary artery disease (CAD) is a leading etiology of heart failure (HF) and serves as a significant therapeutic target to ameliorate HF-associated morbidity and mortality. Key management considerations include pharmacologic treatment, electrophysiological devices, and coronary revascularization, aimed toward preventing CAD progression, left ventricular remodeling, sudden death, and reinfarction. The optimal revascularization strategy for patients with CAD and HF who are surgical candidates requires careful assessment of each patients' unique risk/benefit profile and individual preferences. Several novel pharmacologic agents are in development with hopes of adding to the armamentarium of treatment of CAD and HF.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2026) conducted a review in Coronary artery disease and heart failure. Pharmacologic treatment, electrophysiological devices, and coronary revascularization was evaluated on Prevention of CAD progression, left ventricular remodeling, sudden death, and reinfarction. Pharmacologic treatment, electrophysiological devices, and coronary revascularization target CAD to reduce HF-associated morbidity and mortality (narrative review; no statistical data reported).
Synapse has enriched 10 related papers. Consider them for comparative context: